Related Experiment Video
Updated: Jan 27, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives
Sabrina Falkowski1, Jean-Baptiste Woillard2,3,4
1Department of Oncology, Clinique Chenieux.
Abstract:
Everolimus is a mammalian target of rapamycin (m-TOR) inhibitor that has been approved for the treatment of hormone receptor-positive advanced breast cancer, metastatic renal cancer, and neuroendocrine tumors. Although therapeutic drug monitoring (TDM) of everolimus is well established in the transplantation field, it is not currently performed in oncology. The last consensus conference about the TDM of everolimus states that for the use of everolimus in oncology, "further studies are required to determine the clinical utility of TDM for everolimus in oncology settings." In this review, the authors will discuss the current evidences and perspectives, based on observational studies available, in favor of the TDM of everolimus in oncology focusing on (1) the management of everolimus in routine practice, (2) the prerequisites for TDM of everolimus in oncology, (3) the pharmacodynamics (including a description of the biomarker of resistance and mutations in m-TOR), and (4) a general outlook.
Insights
Therapeutic drug monitoring (TDM) for everolimus, an mTOR inhibitor, is standard in transplantation but not oncology. This review explores evidence supporting TDM
Area of Science:
- Pharmacology
- Oncology
- Drug Monitoring
Background:
- Everolimus, an mTOR inhibitor, treats advanced breast, renal, and neuroendocrine cancers.
- Therapeutic drug monitoring (TDM) is established in transplantation but not routine in oncology for everolimus.
- Current consensus requires further studies on the clinical utility of everolimus TDM in oncology.
Purpose of the Study:
- To review existing evidence and perspectives favoring TDM of everolimus in oncology.
- To discuss the practical management, prerequisites, and pharmacodynamics of everolimus TDM.
- To provide an outlook on the role of TDM in everolimus cancer treatment.
Main Methods:
- Review of observational studies on everolimus use in oncology.
- Analysis of current practices and evidence for TDM.
- Discussion of pharmacodynamic aspects, including resistance biomarkers and mTOR mutations.
Main Results:
- Evidence suggests potential benefits of TDM for everolimus in oncology settings.
- Routine management and prerequisites for TDM implementation are discussed.
- Pharmacodynamic factors influencing everolimus efficacy and resistance are examined.
Conclusions:
- Further research is needed to solidify the role of TDM for everolimus in oncology.
- TDM may offer a valuable tool for optimizing everolimus treatment in cancer patients.
- Understanding pharmacodynamics is crucial for effective TDM strategies in oncology.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring: Overview and Classification
The Evidence for Evolution
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Cardiovascular Drugs: Classification based on Therapeutic Indications

